Journal
MOLECULAR ONCOLOGY
Volume 9, Issue 8, Pages 1599-1611Publisher
WILEY
DOI: 10.1016/j.molonc.2015.04.012
Keywords
beta-catenin; CCL25; CCR9; Drug resistance; Pancreatic cancer
Categories
Funding
- Research Scholar Grant from the American Cancer Society [120687-RSG-11-070-01-TBE]
- City of Hope Comprehensive Cancer Center [P30 CA33572-27]
Ask authors/readers for more resources
Elevated levels of chemoldne receptor CCR9 expression in solid tumors may contribute to poor patient prognosis. In this study, we characterized a novel CCR9-mediated pathway that promotes pancreatic cancer cell invasion and drug resistance, indicating that CCR9 may play a critical role in cancer progression through activation of beta-catenin. We noted that the CCL25/CCR9 axis in pancreatic cancer cells induced the activation of beta-catenin, which enhanced cell proliferation, invasion, and drug resistance. CCR9-mediated activation of beta-catenin and the resulting downstream effects were effectively inhibited by blockade of the PI3K/AKT pathway, but not by antagonism of Wnt. Importantly, we discovered that CCR9/CCL25 increased the lethal dose of gemcitabine, suggesting decreased efficacy of anti-cancer drugs with CCR9 signaling. Through in silico computational modeling, we identified candidate CCR9 antagonists and tested their effects on CCR9/beta-catenin regulation of cell signaling and drug sensitivity. When combined with gemcitabine, it resulted in synergistic cytotoxicity. Our results show that CCR9/beta-catenin signaling enhances pancreatic cancer invasiveness and chemoresistance, and may be a highly novel therapeutic target. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available